NASDAQ$MRSN
Mersana Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Mersana Therapeutics reported financial results for the first quarter ended March 31, 2021 and provided a business update.
Mersana Therapeutics announced the initiation of UPLIFT, a single-arm registrational strategy for evaluating UpRi in platinum-resistant ovarian cancer. The company ended the first quarter of 2021 with $228.4 million in cash and cash equivalents.
- Initiated UPLIFT single-arm registration strategy for evaluation of UpRi in platinum-resistant ovarian cancer.
- UpRi has demonstrated promising activity and a differentiated tolerability profile.
- Remain on track to initiate the UPGRADE umbrella combination study in the third quarter of 2021.
- Ended first quarter of 2021 with $228.4 million in cash.
Headline financials
Revenue & EPS history
Mersana · Revenue · Quarterly
$11K
Forward guidance
The Company expects that its available funds will be sufficient to support its operating plan commitments for approximately two years.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports
+1.4%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+1.3%
Avg return
30 days after
47%
17 / 36 earnings
Positive
+38.9%
Q2 2022
Best reaction
-20.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +2.4% | +0.8% | +3.0% | |
| Q2 2025 | +11.6% | +22.3% | +18.6% | |
| Q1 2025 | -18.5% | -0.2% | -3.6% | |
| Q4 2024 | -8.3% | +3.6% | -36.7% | |
| Q3 2024 | +14.5% | -3.7% | -1.8% | |
| Q2 2024 | -13.4% | -7.2% | +25.2% | |
| Q1 2024 | -20.3% | -23.8% | -37.4% | |
| Q4 2023 | +27.4% | +33.8% | +4.8% | |
| Q3 2023 | -6.5% | -12.9% | +46.8% | |
| Q2 2023 | +0.0% | +4.2% | +6.7% | |
| Q1 2023 | +8.9% | +8.2% | +16.4% | |
| Q4 2022 | +7.0% | +4.4% | -26.3% | |
| Q3 2022 | -11.0% | — | — | |
| Q2 2022 | +38.9% | — | — | |
| Q1 2022 | -11.2% | — | — | |
| Q4 2021 | +14.4% | — | — | |
| Q3 2021 | -1.1% | — | — | |
| Q2 2021 | -2.1% | — | — | |
| Q1 2021 | -5.3% | — | — | |
| Q4 2020 | +7.7% | — | — | |
| Q3 2020 | -4.2% | — | — | |
| Q2 2020 | -1.9% | — | — | |
| Q1 2020 | -3.1% | — | — | |
| Q4 2019 | +3.5% | — | — | |
| Q3 2019 | +7.0% | — | — | |
| Q2 2019 | +2.3% | — | — | |
| Q1 2019 | +14.3% | — | — | |
| Q4 2018 | +4.0% | — | — | |
| Q3 2018 | +7.5% | — | — | |
| Q2 2018 | +0.0% | — | — | |
| Q1 2018 | -3.7% | — | — | |
| Q1 2016 | -8.9% | — | — | |
| Q3 2016 | -4.5% | — | — | |
| Q3 2017 | -5.1% | — | — | |
| Q4 2016 | +3.9% | — | — | |
| Q2 2016 | +3.9% | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro